CG
RVPH

Colony Group’s REVIVA PHARMA HLDGS INC RVPH Stock Holding History

Colony Group’s Portfolio RVPH Stock Details RVPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$834K Buy
8,550
+800
+10% +$74.6K 0.01% 457
2023
Q2 		$908K Buy
7,750
+3,100
+67% +$393K 0.01% 452
2023
Q1 		$390K Buy
+4,650
New +$406K 0.01% 612

Other funds holding RVPH

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $71.1B AUM 128.96% 1-Year Est. Return
ECM
EMC Capital Management Houston, Texas $253M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Belvedere Trading
Belvedere Trading Chicago, Illinois $87.6B AUM 131.08% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Colony Group's RVPH Position: Q3 2023 in Review

Colony Group increased its REVIVA PHARMA HLDGS INC (RVPH) stake by 10% in Q3 2023, buying an estimated $74.6K and bringing the position to 8,550 shares worth $834K. The position accounts for 0.01% of the portfolio, ranked #457.

Colony Group first reported a position in RVPH in Q1 2023 and has held it in 3 quarters since. The position peaked at $908K in Q2 2023. 23 funds tracked by Wall St. Rank hold RVPH as of Q3 2023.

  • Colony Group held 8,550 shares of REVIVA PHARMA HLDGS INC worth $834K as of Q3 2023.
  • Colony Group bought 800 REVIVA PHARMA HLDGS INC shares in Q3 2023, an estimated $74.6K.
  • REVIVA PHARMA HLDGS INC made up 0.01% of Colony Group's portfolio in Q3 2023, its #457 holding.
  • Colony Group first reported a position in REVIVA PHARMA HLDGS INC in Q1 2023 and has held it in 3 quarters since.
  • Colony Group's REVIVA PHARMA HLDGS INC position peaked at $908K in Q2 2023.
  • 23 funds tracked by Wall St. Rank held REVIVA PHARMA HLDGS INC as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.